Recent knowledge on squamous cell carcinoma of the oral cavity: Contributing factors, underlying molecular pathways, and current attitudes in the therapeutic approaches.
{"title":"Recent knowledge on squamous cell carcinoma of the oral cavity: Contributing factors, underlying molecular pathways, and current attitudes in the therapeutic approaches.","authors":"Reza Mahmoudi Anzabi, Amir Hossein Davodpour, Soroush Ghodratizadeh, Dorsa Nikeghbal, Azita Sadeghzade, Meysam Mohammadikhah, Sajjad Rostamzadeh","doi":"10.22088/IJMCM.BUMS.14.3.928","DOIUrl":null,"url":null,"abstract":"<p><p>Oral cavity squamous cell carcinoma (OCSCC) is a prevalent malignancy associated with considerable morbidity and mortality. This article offers a comprehensive overview of its major risk factors, molecular characteristics, and emerging therapeutic approaches. Key risk factors include tobacco use, alcohol consumption, and environmental exposures such as air pollution. Viral infections, particularly with Epstein-Barr Virus (EBV) and high-risk genotypes of Human Papillomaviruses (HPV), are also implicated in OCSCC pathogenesis. At the molecular level, OCSCC is characterized by aberrant expression of growth factors, especially transforming growth factor α (TGF-α) and epidermal growth factor receptor (EGFR). EGFR overexpression, often due to gene amplification, is closely associated with tumor progression and poor clinical outcomes. These insights into molecular pathways are guiding the development of targeted therapies. Innovative treatments are being explored, including combination therapies such as metformin with 4SC-202, which show promise in reducing tumor cell migration and enhancing chemotherapy sensitivity. Additionally, nanoengineered formulations of cisplatin aim to improve drug delivery specificity and minimize systemic toxicity, offering a more patient-friendly approach. The article emphasizes the need for continued investigation into novel therapeutic strategies and a deeper understanding of the molecular basis of OCSCC to improve treatment outcomes. Future research priorities include the identification of new risk factors, refinement of induction chemotherapy protocols, and incorporation of personalized treatment strategies. Addressing these areas is crucial for advancing prevention, enabling early diagnosis, and improving survival and quality of life for patients with OCSCC. This work supports ongoing progress in oral cancer research and clinical care.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":"14 3","pages":"928-948"},"PeriodicalIF":0.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12664692/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Molecular and Cellular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22088/IJMCM.BUMS.14.3.928","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Oral cavity squamous cell carcinoma (OCSCC) is a prevalent malignancy associated with considerable morbidity and mortality. This article offers a comprehensive overview of its major risk factors, molecular characteristics, and emerging therapeutic approaches. Key risk factors include tobacco use, alcohol consumption, and environmental exposures such as air pollution. Viral infections, particularly with Epstein-Barr Virus (EBV) and high-risk genotypes of Human Papillomaviruses (HPV), are also implicated in OCSCC pathogenesis. At the molecular level, OCSCC is characterized by aberrant expression of growth factors, especially transforming growth factor α (TGF-α) and epidermal growth factor receptor (EGFR). EGFR overexpression, often due to gene amplification, is closely associated with tumor progression and poor clinical outcomes. These insights into molecular pathways are guiding the development of targeted therapies. Innovative treatments are being explored, including combination therapies such as metformin with 4SC-202, which show promise in reducing tumor cell migration and enhancing chemotherapy sensitivity. Additionally, nanoengineered formulations of cisplatin aim to improve drug delivery specificity and minimize systemic toxicity, offering a more patient-friendly approach. The article emphasizes the need for continued investigation into novel therapeutic strategies and a deeper understanding of the molecular basis of OCSCC to improve treatment outcomes. Future research priorities include the identification of new risk factors, refinement of induction chemotherapy protocols, and incorporation of personalized treatment strategies. Addressing these areas is crucial for advancing prevention, enabling early diagnosis, and improving survival and quality of life for patients with OCSCC. This work supports ongoing progress in oral cancer research and clinical care.
期刊介绍:
The International Journal of Molecular and Cellular Medicine (IJMCM) is a peer-reviewed, quarterly publication of Cellular and Molecular Biology Research Center (CMBRC), Babol University of Medical Sciences, Babol, Iran. The journal covers all cellular & molecular biology and medicine disciplines such as the genetic basis of disease, biomarker discovery in diagnosis and treatment, genomics and proteomics, bioinformatics, computer applications in human biology, stem cells and tissue engineering, medical biotechnology, nanomedicine, cellular processes related to growth, death and survival, clinical biochemistry, molecular & cellular immunology, molecular and cellular aspects of infectious disease and cancer research. IJMCM is a free access journal. All open access articles published in IJMCM are distributed under the terms of the Creative Commons Attribution CC BY. The journal doesn''t have any submission and article processing charges (APCs).